197 related articles for article (PubMed ID: 23632354)
1. Ipilimumab-induced perforating colitis.
Mitchell KA; Kluger H; Sznol M; Hartman DJ
J Clin Gastroenterol; 2013 Oct; 47(9):781-5. PubMed ID: 23632354
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
4. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
Klair JS; Girotra M; Hutchins LF; Caradine KD; Aduli F; Garcia-Saenz-de-Sicilia M
Dig Dis Sci; 2016 Jul; 61(7):2132-9. PubMed ID: 26846115
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab: a novel treatment for ipilimumab-induced colitis.
Hsieh AH; Ferman M; Brown MP; Andrews JM
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539137
[TBL] [Abstract][Full Text] [Related]
10. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
11. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
[TBL] [Abstract][Full Text] [Related]
12. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.
Merrill SP; Reynolds P; Kalra A; Biehl J; Vandivier RW; Mueller SW
Ann Pharmacother; 2014 Jun; 48(6):806-10. PubMed ID: 24651165
[TBL] [Abstract][Full Text] [Related]
13. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
14. Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma.
Shepard B; Trower C; Hendrickson S
J Am Osteopath Assoc; 2018 Jan; 118(1):40-44. PubMed ID: 29309091
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
16. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
18. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.
Lord JD; Hackman RC; Moklebust A; Thompson JA; Higano CS; Chielens D; Steinbach G; McDonald GB
Dig Dis Sci; 2010 May; 55(5):1396-405. PubMed ID: 19507029
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]